Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shenzhen Salubris May Acquire Liver Cancer Candidate from US NIH

publication date: Aug 9, 2017
Salubris Biotherapeutics, the US arm of Shenzhen Salubris Pharma, has negotiated a tech transfer with the US National Institutes of Health for a potential liver cancer drug. The rights are for a bispecific antibody-drug conjugate targeting GPC3, an antigen expressed in liver cancer. According to the NIH, opponents have until August 22 to object to the agreement; otherwise, it will proceed. Some elected US officials oppose these agreements, arguing the US government paid for the basic research, but retains no control over the price the licensee will charge. More details....

Stock Symbol: (SZE: 2294)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital